MicuRx 盟科医药  
MicuRx 致力于发现和开发治疗由耐药菌引起感染的新型抗生素。该公司将其美国研发团队的丰富经验与中国高品质、高经济效益的药物研发优势相结合，逐渐建立起一个治疗各类耐药革兰氏阳性和阴性菌新药的平台。该公司在美国加州硅谷和中国张江设有研发实验室。MicuRx 在首轮风险融资中从 Morningside Group 和 Devon Park Bioventures  募集了1200万美元。

 
盟科医药技术（上海）有限公司成立于2007年7月,致力于开发拥有自主知识产权的新一代抗菌药物，以解决日益严重的、由于耐药菌引起的感染，并在未来实现其工业生产和商业化。
经过三年多的高效运转，公司自主研发的第一个候选1.1类新药MRX-I，其前期研究得到了国家“十一五重大新药创制”的一定支持，现已完成了前期药学，毒理和生产工艺的研究，于2009年在中国申报临床试验（IND），并已取得中国食品药品监督管理局进行临床试验的批文，已经进入一期人体临床试验。该1.1类新药有望于2015年前后在中、美同时上市，预期全球市场可达十亿美元。
   


MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient infrastructure and scientific resources available in China. This hybrid business model enables MicuRx to implement an accelerated global development strategy with a goal of completing Phase II trials for its drug candidates in both the United States and China.

Infections due to multi-drug resistant bacteria have become a major threat to public health. In particular, methicillin-resistant Staphylococcus aureus (MRSA) has quickly spread from the hospital setting into the community and vancomycin-resistant enterococci (VRE) now represents at least 30% of all hospital enterococci infections. Importantly, bacteria continue to evolve and new strains of bacteria are resistant to even the newest antibiotics.

Using its proprietary drug discovery platform, MicuRx has generated a broad pipeline of antimicrobial agents to treat Gram-positive, Gram-negative and fungal infections. MicuRx's lead drug candidate is MRX-I, a next-generation oxazolidinone antibiotic with a superior therapeutic window projected to offer significant clinical differences over existing drugs. MicuRx filed its first Investigational New Drug (IND) application in China and received "Special Review" status from the State Food and Drug Administration.

In addition to its internal pipeline, MicuRx and Pfizer have entered a collaboration agreement to discover and develop new therapeutic agents to treat drug-resistant tuberculosis. All collaboration research will be conducted at the ZhangJiang High-Tech Park in Shanghai, China.